Fig. 1

LCL161 and VSV^ΔM51 combination therapy induces CD8⁺ T-cell-mediated tumor regression independent of TNFR1 signaling in cancer cells. a Overall survival of EMT6 tumor-bearing mice treated with LCL161 ± VSV^ΔM51 ± CD8 neutralizing antibody (or isotype control; triplicate experiments; log-rank test). b Overall survival of EMT6 tumor-bearing mice treated with LCL161 + VSV^ΔM51 ± CD4 neutralizing antibody (or isotype control; duplicate experiments; log-rank test). c Cell viability of parental EMT6 cells and three EMT6^TNFR1-CRISPR clones assayed for TNFR1 bioactivity by treatment with LCL161 + TNFα (100 ng mL⁻¹), measured by Alamar Blue 48 h later (n = 3 biological replicates per experiment; triplicate experiments; mean ± SD; ANOVA with Tukey’s multiple comparisons test). d–f Overall survival of EMT6^TNFR1+/+ (d clone 1-4) and EMT6^TNFR1−/− (e, f clones 2–10 and 3–12) bearing mice treated with LCL161 + VSV^ΔM51 (duplicate experiments; log-rank test). g–i Overall survival of 76–9 g, 4T1 h and M3-9-M i tumor-bearing mice treated with LCL161 + VSV^ΔM51 (M3-9-M: triplicate experiments; 76–9 and 4T1: single experiment). Effect of CD4 or CD8 (or isotype control) neutralization is shown for M3-9-M (single experiment; log-rank test)